Company Profile

BioPancreate Inc
Profile last edited on: 9/13/13      CAGE: 6BUZ6      UEI:

Business Identifier: therapies that may prevent, reverse, or improve diabetes using genetically enhanced commensal bacteria.
Year Founded
2010
First Award
2012
Latest Award
2012
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

555 East Lancaster Avenue Suite 510
Radnor, PA 19087
   (610) 254-9225
   N/A
   N/A
Location: Single
Congr. District: 05
County: Delaware

Public Profile

BioPancreate, Inc., is a biopharmaceutical company established to develop novel oral therapies based on genetic modification of human commensal bacteria for treating major human diseases, e.g., diabetes (T1D and T2D) and other endocrine and gastrointestinal disorders.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2012 1 NIH $168,530
Project Title: Bacterially-Secreted Glp-1 Induced Reprogramming Of Intestinal Cells As A Treatme

Key People / Management

  Theodore Koziol -- President & Co-Founder

  Joseph Reiser